Detalhe da pesquisa
1.
Evaluation of in vitro antiviral activity of SARS-CoV-2 Mpro inhibitor pomotrelvir and cross-resistance to nirmatrelvir resistance substitutions.
Antimicrob Agents Chemother
; 67(11): e0084023, 2023 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37800975
2.
Nonstructural protein 5A (NS5A) and human replication protein A increase the processivity of hepatitis C virus NS5B polymerase activity in vitro.
J Virol
; 89(1): 165-80, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25320291
3.
Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit.
Antimicrob Agents Chemother
; 59(3): 1569-82, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25547360
4.
Telaprevir-based treatment effects on hepatitis C virus in liver and blood.
Hepatology
; 60(6): 1826-37, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24811404
5.
Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment.
J Virol
; 87(3): 1544-53, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23152524
6.
SARS-CoV-2 viral dynamics in a placebo-controlled phase 2 study of patients infected with the SARS-CoV-2 Omicron variant and treated with pomotrelvir.
Microbiol Spectr
; 12(2): e0298023, 2024 Feb 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38197702
7.
Restoration of the activated Rig-I pathway in hepatitis C virus (HCV) replicon cells by HCV protease, polymerase, and NS5A inhibitors in vitro at clinically relevant concentrations.
Antimicrob Agents Chemother
; 57(9): 4417-26, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23836176
8.
Accelerating antiviral drug discovery: lessons from COVID-19.
Nat Rev Drug Discov
; 22(7): 585-603, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37173515
9.
Compensatory substitutions in the HCV NS3/4A protease cleavage sites are not observed in patients treated unsuccessfully with telaprevir combination treatment.
Virol J
; 9: 147, 2012 Aug 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-22866919
10.
A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants.
PLoS Comput Biol
; 6(4): e1000745, 2010 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20419154
11.
HVR-1 heterogeneity during treatment with telaprevir with or without pegylated interferon alfa-2a.
Scand J Gastroenterol
; 46(11): 1362-8, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21815864
12.
Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs).
J Antimicrob Chemother
; 65(2): 202-12, 2010 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19903720
13.
Barrier to resistance: lessons from 2 direct-acting hepatitis C virus inhibitors, MK-5172 and Sofosbuvir.
Clin Infect Dis
; 59(12): 1675-7, 2014 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25266288
14.
Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors.
Curr Opin Pharmacol
; 8(5): 522-31, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18835365
15.
Viral and cellular RNA helicases as antiviral targets.
Nat Rev Drug Discov
; 4(10): 845-53, 2005 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-16184083
16.
Merimepodib, an IMPDH inhibitor, suppresses replication of Zika virus and other emerging viral pathogens.
Antiviral Res
; 149: 34-40, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29126899
17.
Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG.
Gastroenterology
; 140(3): 755-60, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21255574
18.
The HCV Revolution Did Not Happen Overnight.
ACS Med Chem Lett
; 5(3): 214-220, 2014 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-24672647
19.
Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials.
PLoS One
; 7(4): e34372, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22511937
20.
Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus.
Nat Biotechnol
; 29(11): 993-1003, 2011 Nov 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-22068541